MedTrace Logo

Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin

NCT01178138 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-12-30

Study results available
· View outcomes & findings →

Summary

This protocol will test the safety, effectiveness and the metabolism and action of prazosin as a potential therapy for methamphetamine abuse. This will be accomplished by performing a series of human laboratory studies. In each of these studies, the safety and effectiveness of the test medication (prazosin) in the treatment of methamphetamine effects will be determined. The study hypothesis is that prazosin will block the methamphetamine receptor function, reducing the reinforcing effects of central nervous system effects in humans.

Conditions

  • Continuous Methamphetamine Abuse

Interventions

DRUG

Prazosin

Prazosin or oral placebo given before methamphetamine or iv placebo to determine effects of prazosin on methamphetamine.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Arkansas

    lead OTHER

Principal Investigators

  • William B Gentry, MD · University of Arkansas

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01178138 on ClinicalTrials.gov